Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age

References

• World Health Organization (WHO). Pneumococcal vaccines WHO position paper–2012. Wkly Epidemiol Rec. 2012;87:129–144.
   PubMedGoogle Scholar
• Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE. 2013;8:e60273.
   PubMed Web of Science ®Google Scholar
• Muhammad RD, Oza-Frank R, Zell E, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis. 2013;56:e59–67.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1–24.
   PubMedGoogle Scholar
• Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1:ofu024.
   PubMedGoogle Scholar
• Pneumovax 23 (pneumococcal vaccine polyvalent). Full prescribing information. Whitehouse Station, NJ: Merck & Co., Inc.; 2015.
   Google Scholar
• 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008;83:373–384.
   PubMedGoogle Scholar
• Dear K, Holden J, Andrews R, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2003;4:CD000422.
   PubMedGoogle Scholar
• Musher DM, Rueda-Jaimes AM, Graviss EA, et al. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis. 2006;43:1004–1008.
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Cmaj. 2009;180:48–58.
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;1:CD000422.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59:1102–1106.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease. In: Hamborsky J, Kroger A, Wolfe S, Eds. Epidemiology and prevention of vaccine-preventable diseases. 13th. Public Health Foundation: Washington, DC; 2015.
   Google Scholar
• Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30:6802–6808.
   PubMed Web of Science ®Google Scholar
• Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med. 2000;160:2633–2638.
   PubMed Web of Science ®Google Scholar
• Pedersen RH, Lohse N, Ostergaard L, et al. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med. 2011;12:323–333.
   PubMed Web of Science ®Google Scholar
• Metersky ML, Dransfield MT, Jackson LA. Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine? Chest. 2010;138:486–490.
   PubMed Web of Science ®Google Scholar
• Macleod CM, Hodges RG, Heidelberger M, et al. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med. 1945;82:445–465.
   Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747–1755.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009;27:1504–1510.
   PubMed Web of Science ®Google Scholar
• Nichol KL, Baken L, Wuorenma J, et al. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med. 1999;159:2437–2442.
   PubMed Web of Science ®Google Scholar
• Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a veterans administration cooperative study. N Engl J Med. 1986;315:1318–1327.
   PubMed Web of Science ®Google Scholar
• Koivula I, Sten M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med. 1997;103:281–290.
   PubMed Web of Science ®Google Scholar
• Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal vaccination study group. Lancet. 1998;351:399–403.
   PubMed Web of Science ®Google Scholar
• Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999;17:2493–2500.
   PubMed Web of Science ®Google Scholar
• Davis AL, Aranda CP, Schiffman G, et al. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A Pilot Study Chest. 1987;92:204–212.
   Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–825.
   PubMed Web of Science ®Google Scholar
• Khoie T, Tiernan R, deVore N. FDA briefing document. prenar 13 (PCV13): pneumococcal 13-valent conjugate vaccine (Diphtheria CRM197 Protein). Applicant: Wyeth Pharmaceuticals Inc; Silver Spring, MA: US Food and Drug Administration. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM279681.pdf Last accessed January 8, 2017.
   Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–1125.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–35.
   Google Scholar
• Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Streptococcus pneumoniae, 1998–2015. In: Active bacterial core surveillance report, emerging infections program network, Streptococcus pneumoniae. 1998–2015. Atlanta, GA: Centers for Disease Control and Prevention; 2016. Available at: http://www.cdc.gov/abcs/reports-findings/surv-reports.html.
   Google Scholar
• Pilishvili T, Ahmed S, Xing W, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in the U.S. on invasive pneumococcal disease (IPD) among adults with chronic conditions. Presented at: International Symposium on Pneumococci and Pneumococcal Diseases; June 26–30, 2016; Glasgow, UK.
   Google Scholar
• Active Bacterial Core Surveillance T.  Atlanta, GA: Centers for Disease Control and Prevention. [Cited 2017 Mar 13]. Available at: http://www.cdc.gov/abcs/reports-findings/surv-reports.html
   Google Scholar
• Kyaw MH, Rose CE Jr., Fry AM, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–386.
   PubMed Web of Science ®Google Scholar
• Weycker D, Strutton D, Edelsberg J, et al. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955–4960.
   PubMed Web of Science ®Google Scholar
• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20:45–51.
   PubMed Web of Science ®Google Scholar
• Pride MW, Huijts SM, Wu K, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol. 2012;19:1131–1141.
   PubMed Web of Science ®Google Scholar
• Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax. 2012;67:540–545.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, et al. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2:387–394.
   PubMed Web of Science ®Google Scholar
• Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–427.
   PubMed Web of Science ®Google Scholar
• Marston BJ, Plouffe JF, File TM Jr., et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-based pneumonia incidence study group. Arch Intern Med. 1997;157:1709–1718.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Bewick T, Sheppard C, et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015;45:1632–1641.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179–1186.
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369:155–163.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–e111.
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology & mortality. Clin Infect Dis. 2017;65(11):1806–1812.
   Web of Science ®Google Scholar
• McLaughlin JM, Johnson MH, Kagan SA, et al. Clinical and economic burden of community-acquired pneumonia in the veterans health administration, 2011: a retrospective cohort study. Infection. 2015;43:671–680.
   PubMed Web of Science ®Google Scholar
• Yu H, Rubin J, Dunning S, et al. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc. 2012;60:2137–2143.
   PubMed Web of Science ®Google Scholar
• Sherwin RL, Gray S, Alexander R, et al. Distribution of PCV13-serotype Streptococcus pneumoniae in adults aged ≥50 years presenting to select US hospitals with radiographically confirmed community-onset pneumonia (CAP/HCAP). Presented at: IDWeek; October 16–21, 2012; San Diego, CA.
   Google Scholar
• Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis. 2013;208:1813–1820.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Wunderink RG, Williams D, et al. Distribution of pneumococcal serotypes detected through urine analysis among US adults hospitalized with pneumonia after introduction of PCV13. Presented at: 9th International Symposium on Pneumococci and Pneumococcal Diseases; March 9–13, 2014; Hyderabad, India.
   Google Scholar
• Ramirez J, The 1147 study group. Burden of community-acquired pneumonia due to PCV-13 Streptococcus pneumoniae serotypes among hospitalized adults in the United States. Presented at: IDWeek 2017; October 4–8, 2017; San Diego, CA.
   Google Scholar
• Sato R, Gomez Rey G, Nelson S, et al. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged >/=50 years. Appl Health Econ Health Policy. 2013;11:251–258.
   PubMedGoogle Scholar
• Weycker D, Farkouh RA, Strutton DR, et al. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res. 2016;16:182.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR - Morbidity & Mortality Weekly Report. 2012;61:816–819.
   PubMedGoogle Scholar
• French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362:812–822.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention Department of Health and Human Services. Advisory Committee on Immunization Practices (ACIP) Summary Report June 20– 212012. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun12.pdf [ Last accessed August 7, 2017].
   Google Scholar
• Centers for Disease Control and Prevention Department of Health and Human Services. Advisory Committee on Immunization Practices (ACIP) Summary Report February 22– 232012. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-feb12.pdf [ Last accessed August 7, 2017].
   Google Scholar
• Bryant KA, Frenck R, Gurtman A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18–49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2015;33:5854–5860.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, Van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013;31:3577–3584.
   PubMed Web of Science ®Google Scholar
• Suaya JA, Jiang Q, Bonten M, et al. Post-hoc analysis of the 13-valent polysaccharide conjugate vaccine efficacy against vaccine-serotype pneumococcal community acquired pneumonia in at-risk older adults. Presented at: International Symposium on Pneumococci and Pneumococcal Diseases; June 26–30, 2016; Glasgow, UK.
   Google Scholar
• Data on File. Pfizer Inc. AIDS. Collegeville, PA: Lippincott, Williams and Wilkins, UK; 2017.
   Google Scholar
• Bhorat AE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. Aids. 2015;29:1345–1354.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Ljungman P, Juergens C, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >/=2 years: an open-label study. Clin Infect Dis. 2015;61:313–323.
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Watson W, Brinson C, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis. 2015;212:18–27.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19:1296–1303.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31:3585–3593.
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine. 2014;32:2364–2374.
   PubMed Web of Science ®Google Scholar
• Williams WW, Lu PJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations - United States, 2014. MMWR Surveill Summ. 2016;65:1–36.
   PubMed Web of Science ®Google Scholar
• Releases HHS Plan to improve US adult immunization rates. [Cited 2017 Mar 17]. Available at: https://www.hhs.gov/ash/about-ash/news/2016/hhs-releases-plan-to-improve-us-adult-immunization-rates/index.html
   Google Scholar
• Stoecker C, Kim L, Gierke R, et al. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31:901–908.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, et al. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. Jama. 2012;307:804–812.
   PubMed Web of Science ®Google Scholar
• Nuorti P, Reingold A. Preventing pneumococcal infections in older adults. Lancet Respir Med. 2015;3:834–836.
   PubMed Web of Science ®Google Scholar
• Pisano J, Cifu AS. Use of pneumococcal vaccine in adults. Jama. 2015;313:719–720.
   PubMed Web of Science ®Google Scholar
• Schuchat A. Pneumococcal prevention gets older and wiser. JAMA Intern Med. 2015;Oct26:1–2 [Epub ahead of print].
   Google Scholar
• Weinberger DM, Shapiro ED. Pneumococcal conjugate vaccines for adults: reasons for optimism and for caution. Hum Vaccin Immunother. 2014;10:1334–1336.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Swerdlow DL, Isturiz RE, et al. Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: current and future implications. Vaccine. 2017;35:5360–5365.
   PubMed Web of Science ®Google Scholar